Harald Janovjak Bends Cells and Receptors to His Will

The 38-year-old synthetic biologist comes from a long line of tinkerers and engineers.

Written byAggie Mika
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

© STEFAN FUERTBAUERWhen Harald Janovjak filed his first patent describing the cell growth–regulating receptors he had engineered to be activated by light, he stumbled upon his great-grandfather’s 1920 patent for a device that projected color onto movie screens. Janovjak comes from an impressive line of engineers stretching back four generations. But he says he was pleasantly surprised to find that nearly a century later, “we’re still tinkering with light-based things.”

As a child growing up in Switzerland, Janovjak was always building things with his father. “We would inherit bicycles from my uncles or my older cousins, and we would take them apart and modify them.” The acumen he developed for disassembling things, tweaking them, and putting them back together has served him well as a synthetic physiologist.

Janovjak embarked on a career in science as a third-year undergraduate at the University of Basel, after a survey course in biophysics introduced him to microscopist Daniel Müller. In his lab, Müller had pioneered an imaging technique using atomic force microscopy “to visualize single membrane proteins in their native membranes,” says Janovjak. He was hooked, and recalls begging Müller for a spot on his team.

Janovjak’s drive as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

October 2017

A Natural Archive

The practical challenges of storing data in DNA

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies